ONCY
Oncolytics Biotech·NASDAQ
--
--(--)
--
--(--)
5.04 / 10
Netural
Analyst coverage is thin: one Strong‑Buy from HC Wainwright, yielding a neutral sentiment score (5.04). Fund‑flow is good (7.32/10) but all size‑segments show negative trends despite modest inflow ratios (~0.47). Overall, capital interest is positive while analyst confidence is limited.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-17
InstitutionHC Wainwright & Co.
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for ONCY?
- ONCY holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.04/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
